Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P371

Concentrations of 6-thioguanine nucleotide correlate with both infliximab and adalimumab levels in patients with inflammatory bowel disease on combination therapy

Authors:

O. Kelly*, A. Trajkovski, A. Weizman, G. Nguyen, A. H. Steinhart, M. Silverberg, K. Croitoru

Mount Sinai Hospital, Centre for Inflammatory Bowel Disease. Suite 437, Toronto, Canada

P372

A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis*

Authors:

H. H. Radeke*1, 2, J. Stein1, 3, W. Kruis4

1Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 2Pharmazentrum Frankfurt, Hospital of the Goethe University Frankfurt, Frankfurt/Main, Germany, 3DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 4LKP, Evangelisches Krankenhaus Kalk, Cologne, Germany

P373

Adjunctive hyperbaric oxygen therapy promotes successful healing in patients with refractory Crohn’s disease

Authors:

M. Ribeiro Feitosa1, R. S. Parra*1, O. Feres Filho2, J. J. Ribeiro da Rocha1, O. Féres1

1University of Sao Paulo, Surgery and Anatomy, Ribeirao Preto SP, Brazil, 2University of Sao Paulo, Department of Surgery and Anatomy, Ribeirao Preto SP, Brazil

P374

Efficacy of a micronised, dispersible ferric pyrophosphate in children with anaemia associated with inflammatory bowel disease.

Authors:

A. Wegner*1, G. Mierzwa2, S. Wiecek3, A. Korlatowicz- Bilar4, M. Dadalski5, B. Korczowski6, J. Kierkus7

1Public Children’s Clinical Hospital, Warszawa, Poland, 2Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Chair of Vascular and Internal Diseases,, Bydgoszcz, Poland, 3Medical University of Silesia, Department of Paediatrics,, Katowice, Poland, 4Children’s Hospital, Department of Paediatrics, Gastroenterology and Rheumatology, Szczecin, Poland, 5Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology and Eating Disorders,, Warsaw, Poland, 6University of Rzeszów, Department of Paediatrics and paediatric Gastroenterology State Hospital No 2, Rzeszów, Poland, 7Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology and Eating Disorders, Warsaw, Poland

P375

Long-term outcomes after primary infliximab treatment failure in patients with inflammatory bowel disease

Authors:

S. Buhl*, C. Steenholdt, M. Borghede, M. Rasmussen, J. Brynskov, O. Ø. Thomsen, M.A. Ainsworth

Copenhagen University Hospital, Herlev, Department of Gastroenterology, Herlev, Denmark

P376

Therapy refractory ulcerative colitis patients may benefit from appendectomy: early result from the PASSION study

Authors:

S. Sahami*1, C. Buskens1, D. Winter2, S. Martin2, P. Tanis1, G. van den Brink3, M. Löwenberg3, G. Cullen4, H. Mulcahy4, G. Doherty4, C. Ponsioen3, G. D’Haens3, W. Bemelman1

1Academic Medical Centre, Surgery, Amsterdam, Netherlands, 2St. Vincent’s University Hospital, Surgery, Dublin, Ireland, 3Academic Medical Centre, Gastroenterology & Hepatology, Amsterdam, Netherlands, 4St. Vincent’s University Hospital, Gastroenterology & Hepatology, Dublin, Ireland

P377

Serum adalimumab trough levels required for mucosal healing during maintenance therapy in patients with Crohn’s disease

Authors:

H. Imaeda*, Y. Morita, T. Fujimoto, K. Takahashi, M. Shioya, A. Nishida, O. Inatomi, S. Bamba, M. Sasaki, T. Tsujikawa, M. Sugimoto, A. Andoh

Shiga University of Medical Science, Department of Medicine, Otsu, Japan

P378

The outcomes of a clinical care pathway for inflammatory bowel disease surgery

Authors:

A. Platt*1, A. Lightner2, R. Jacobs1, D. Sagar1, W. van Deen1, T. Hommes1, S. Reardon3, J. Sack3, D. Hommes1

1UCLA Centre for Inflammatory Bowel Diseases, Department of Digestive Diseases, Los Angeles, California, United States, 2Mayo Clinic College of Medicine, Division of Colon and Rectal Surgery, Rochester, Minnesota, United States, 3UCLA, Department of Colorectal Surgery, Los Angeles, California, United States

P379

Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation

Authors:

M. S. Prüß*, A. Farmer, B. Siegmund

Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany

P380

Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn’s disease

Authors:

E. Szymanska*1, M. Dadalski2, S. Szymanska3, W. Grajkowska3, M. Pronicki3, K. Jaroslaw2

1Children’s Memorial Health Institute, Department of Paediatrics, Nutrition and Metabolic Disorders, Warsaw, Poland, 2Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology and Feeding Disorders, Warsaw, Poland, 3Children’s Memorial Heath Institute, Department of Pathology, Warsaw, Poland

P381

An observational study of adverse events of patients with inflammatory bowel disease receiving parenteral iron

Authors:

A. Wilson*, E. Murray, G. B. Turner

Belfast Trust, Belfast, United Kingdom

P382

Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease

Authors:

R. Muhammed*, L. Whyte, S. Protheroe, R. Bremner, W. Haller, T. Wong

Birmingham Children’s Hospital, Gastroenterology, Birmingham, United Kingdom

P383

Short- and long-term outcomes of infliximab and calcineurin inhibitor treatment for steroid-refractory ulcerative colitis

Authors:

S. Motoya*, M. Miyakawa, M. Nasuno, H. Tanaka

Sapporo-Kosei General Hospital, IBD Centre, Sapporo, HOKKAIDO, Japan

P384

The usefulness of salazosulfapyridine for 
patients with ulcerative colitis refractory to mesalazine

Authors:

T. Yoshino*, S. Yazumi

Kitano Hospital, Division of Gastroenterology and Hepatology, Digestive Disease Centre, Osaka, Japan

P385

Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF

Authors:

N. Viazis*1, M. Giakoumis1, G. Bamias2, D. Goukos2, T. Koukouratos1, J. Anastasiou1, K. Katopodi1, S. Ladas2, D. Karamanolis1

1Evangelismos Hospital, Gastroenterology Department, Athens, Greece, 2Kapodistrian University of Athens, Laikon Hospital, Academic Department of Gastroenterology, Athens, Greece

P386

Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in Germany

Authors:

B. Bokemeyer*1, T. Krummenerl2, C. Maaser3, J. Büning4, R. Atreya5, A. Lügering6, U. Helwig7, P. Jessen8, P. Hartmann9, S. Schreiber10

1Gastroenterology Practice Minden, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany, Minden, Germany, 2Gastroenterology Practice, Gastroenterology, Münster, Germany, 3University Teaching Hospital Lüneburg, IBD Outpatient Clinic and Department of Geriatric Medicine, Lüneburg, Germany, 4University Hospital Schleswig-Holstein, Campus Lübeck, Medical Department I, Gastroenterology, Lübeck, Germany, 5University of Erlangen-Nuremberg, Department of Medicine 1, Erlangen, Germany, 6Gastroenterology Practice Münster, Münster, Germany, 7Gastroenterology Practice Oldenburg, Oldenburg, Germany, 8Gastroenterology Practice, Gastroenterology, Altenholz, Germany, 9Gastroenterology Practice, Minden, Germany, 10Christian-Albrechts-Universität, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany

P387

Does standard therapy in paediatric Crohn’s disease really prevent our patients from the need of early initiation of anti-TNF treatment?

Authors:

P. Domínguez Sánchez*, G. Pujol Muncunill, S. Pinillos Pison, V. Vila Miravet, J. Martín de Carpi

Unit for the Comprehensive Care of Paediatric Inflammatory Bowel Disease. Department of Paediatric Gastroenterology, Hepatology and Nutrition. Hospital Sant Joan de Déu, Barcelona, Spain

P388

Clinical care pathways are needed to decrease variability in the management of the hospitalised ulcerative colitis patient

Authors:

S. Shah*, S. Naymagon, B. Cohen, B. Sands, M. Dubinsky

Mount Sinai Hospital, Gastroenterology, New York, New York, United States

P389

The value of oxidative stress parameters to predict histological severity in ulcerative colitis

Authors:

B. Canbakan*1, K. Atay1, E. Koroglu1, M. Tuncer1, H. Senturk2

1Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey, 2Bezmialem University School of Medicine, Gastroenterology, Istanbul, Turkey

P390

To double dose or not to double dose? That is the question: Single centre experience in the use of infliximab antibodies and levels in a paediatric IBD (pIBD) cohort

Authors:

B. Huggett*, S. Sider, S. Chadokufa, N. Acton, N. Shah, F. Kiparissi

Great Ormond Street Hospital, London, United Kingdom